Alnylam Pharmaceuticals, Inc. Share Price

Equities

ALNY

US02043Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 24/04/2024 BST 5-day change 1st Jan Change
143.8 USD -1.55% Intraday chart for Alnylam Pharmaceuticals, Inc. -1.99% -24.87%
Sales 2024 * 1.85B 149B Sales 2025 * 2.26B 182B Capitalization 18.47B 1,483B
Net income 2024 * -515M -41.34B Net income 2025 * -243M -19.51B EV / Sales 2024 * 9.79 x
Net cash position 2024 * 340M 27.26B Net cash position 2025 * 599M 48.05B EV / Sales 2025 * 7.9 x
P/E ratio 2024 *
-35.6 x
P/E ratio 2025 *
-83.4 x
Employees 2,100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.59%
More Fundamentals * Assessed data
Dynamic Chart
Sector Update: Health Care Stocks Flat to Higher Premarket Monday MT
Sector Update: Health Care MT
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint MT
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower... Our Logo
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension CI
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Canaccord Genuity ?Genetic Medicine for Generalists?, Mar-25-2024 01:00 PM
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-20-2024 10:00 AM
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM
Alnylam Pharmaceuticals Says Phase 2 Study of Hypertension Drug Zilebesiran Meets Primary Endpoint MT
Transcript : Alnylam Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 09:10 AM
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives CI
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,540,071, According to a Recent SEC Filing MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $455,357, According to a Recent SEC Filing MT
How long will this bullish phase last? Our Logo
More news

Latest transcript on Alnylam Pharmaceuticals, Inc.

1 day-1.55%
1 week-1.99%
Current month-3.78%
1 month-1.85%
3 months-24.20%
6 months-11.23%
Current year-24.87%
More quotes
1 week
143.50
Extreme 143.5
150.27
1 month
143.50
Extreme 143.5
159.34
Current year
143.50
Extreme 143.5
199.38
1 year
143.50
Extreme 143.5
218.88
3 years
117.58
Extreme 117.58
242.97
5 years
65.81
Extreme 65.81
242.97
10 years
31.38
Extreme 31.38
242.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 18/09/16
Director of Finance/CFO 56 12/08/19
Compliance Officer - 20/09/22
Members of the board TitleAgeSince
Director/Board Member 70 17/12/15
Director/Board Member 72 21/08/22
Director/Board Member 68 09/01/19
More insiders
Date Price Change Volume
24/04/24 143.8 -1.55% 387,925
23/04/24 146.1 +0.19% 543,726
22/04/24 145.8 +0.96% 399,984
19/04/24 144.4 -0.52% 703,168
18/04/24 145.2 -0.11% 398,914

Delayed Quote Nasdaq, April 24, 2024 at 09:00 pm

More quotes
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
146.1 USD
Average target price
220 USD
Spread / Average Target
+50.61%
Consensus